Abys® Medical, deeptech creator of the Surgery 4.0 concept, finalized in August 2021 a fundraising by opening its capital to... View Article
Author Archives for Adeline Chauvigné
ABYS® MEDICAL successfully completes its first Series A of €3 million
5 July 2025Abys® Medical, deeptech creator of the Surgery 4.0 concept, finalized in August 2021 a fundraising by opening its capital to... View Article
Valneva confirms initiation of rolling review with EMA and provides updates on its COVID-19 vaccine program VLA2001
Valneva, a specialty vaccine company, today confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001,... View Article
Valneva confirms initiation of rolling review with EMA and provides updates on its COVID-19 vaccine program VLA2001
5 July 2025Valneva, a specialty vaccine company, today confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001,... View Article
New member | Healshape
Healshape is a regenerative medicine company with the mission to offer the enhanced option of self-tissue regeneration from patient’s own... View Article
New member | Healshape
5 July 2025Healshape is a regenerative medicine company with the mission to offer the enhanced option of self-tissue regeneration from patient’s own... View Article
Pherecydes Pharma strengthens its intellectual property with the first patent granted in Israel
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that... View Article
Pherecydes Pharma strengthens its intellectual property with the first patent granted in Israel
5 July 2025Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that... View Article
OSE Immunotherapeutics provides an update on the first positive results and clinical development of CoVepiT, its multi-target T-cell anti-COVID vaccine
New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy... View Article
OSE Immunotherapeutics provides an update on the first positive results and clinical development of CoVepiT, its multi-target T-cell anti-COVID vaccine
5 July 2025New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy... View Article
Valneva signs purchase agreement with European Commission for its inactivated COVID-19 vaccine VLA2001
Valneva, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission... View Article
Valneva signs purchase agreement with European Commission for its inactivated COVID-19 vaccine VLA2001
5 July 2025Valneva, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission... View Article
New member | Dopharma
DOPHARMA France is a veterinary pharmaceutical company, installed in Vair-sur-Loire (France, 44) for more than 50 years. Through its historical... View Article
New member | Dopharma
5 July 2025DOPHARMA France is a veterinary pharmaceutical company, installed in Vair-sur-Loire (France, 44) for more than 50 years. Through its historical... View Article
Owkin becomes ‘unicorn’ with $180m investment from Sanofi and four new collaborative projects
Owkin and Sanofi are delighted to announce that Owkin is now a ‘unicorn’ – a startup valued at more than... View Article
Owkin becomes ‘unicorn’ with $180m investment from Sanofi and four new collaborative projects
5 July 2025Owkin and Sanofi are delighted to announce that Owkin is now a ‘unicorn’ – a startup valued at more than... View Article
OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
Clinical trial sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics.... View Article
OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
5 July 2025Clinical trial sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics.... View Article
World first: a double forearm transplant thanks to marina lugworms from the company Hemarina
Amrita Institute of Medical Sciences (AIMS) in Kochi, India, Becomes the First Hospital in the World to Carry Out Bilateral... View Article
World first: a double forearm transplant thanks to marina lugworms from the company Hemarina
5 July 2025Amrita Institute of Medical Sciences (AIMS) in Kochi, India, Becomes the First Hospital in the World to Carry Out Bilateral... View Article